keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant therapy

keyword
https://www.readbyqxmd.com/read/29666806/the-frontline-of-esophageal-cancer-treatment-questions-to-be-asked-and-answered
#1
REVIEW
Cheng-Che Tu, Po-Kuei Hsu
Achieving a good treatment for esophageal cancer is a great challenge. For early stage cancer, endoscopic treatment is considered the first line and a possible curative therapy. Chemotherapy, radiotherapy, and surgery are all used for the treatment of locally advanced esophageal cancer, administered either alone or combined. Some combinations have proven to be feasible, effective, and superior, such as neoadjuvant chemoradiation (CRT) plus surgery in the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29666805/surveillance-or-resection-after-chemoradiation-in-esophageal-cancer
#2
REVIEW
Il-Hwan Park, Jae Y Kim
The treatment of locally advanced esophageal cancer continues to evolve. Previously, surgery was considered the foundation of treatment, but chemoradiation (CRT) has taken on a larger role both in the neoadjuvant setting and as definitive treatment. It has become clear that although some patients benefit from esophagectomy after CRT, a large subset of patients likely derive no benefit, and may be harmed by surgery. Some patients are cured from CRT alone and therefore do not need surgery. Another group of patients likely have metastatic disease at the time of local therapy that is just undetected on imaging and also do not benefit from surgery...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29665663/-analysis-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-tch-in-her-2-positive-breast-cancer
#3
L Xu, J M Ye, S N Zhu, J Y Zhao, L Xin, Y J Cheng, Q Liu, H Zhang, S Zhang, X N Duan, Y H Liu
Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Methods: From January 2008 to December 2014, the data of patients diagnosed as early breast cancer in Breast Disease Center of Peking University First Hospital were retrospective reviewed. The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29663352/prognostic-value-of-pathological-node-status-after-neoadjuvant-radiotherapy-for-rectal-cancer
#4
E Duchalais, T Glyn Mullaney, G M Spears, S R Kelley, K Mathis, W S Harmsen, D W Larson
BACKGROUND: The prognostic value of pathological lymph node status following neoadjuvant radiotherapy (ypN) remains unclear. This study was designed to determine whether ypN status predicted overall survival. METHODS: Patients with locally advanced rectal adenocarcinoma who underwent neoadjuvant long-course radiation between 2005 and 2014 were identified from the National Cancer Data Base, and divided into ypN0, ypN1 and ypN2 groups. The primary outcome was overall survival...
April 17, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29663173/current-status-of-neoadjuvant-endocrine-therapy-in-early-stage-breast-cancer
#5
REVIEW
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer...
April 16, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#6
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29661211/predictive-value-of-dynamic-change-of-haemoglobin-levels-during-therapy-on-treatment-outcomes-in-patients-with-enneking-stage-iib-extremity-osteosarcoma
#7
Jian Tu, Lili Wen, Zijun Huo, Bo Wang, Yongqian Wang, Hongyi Liao, Weihai Liu, Xian Zhong, Jianqiu Kong, Mengqi Wang, Gang Huang, Junqiang Yin, Xianbiao Xie, Jingnan Shen
BACKGROUND: We aimed to investigate the roles of hemoglobin (Hb) concentrations and dynamic change during treatment on outcomes of patients with extremity osteosarcoma. METHODS: We retrospectively analysed 133 patients with Enneking stage IIB extremity osteosarcoma who underwent standard treatments, including univariate and multivariate analyses of patient charateritics, Hb concentrations and changes during pretreatment, neoadjuvant, adjuvant chemotherapy, and decreased Hb levels (ΔHb) to assess their prognostic value in 5-year overall survival (OS) and lung metastasis-free survival (LMFS)...
April 16, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29659933/circulating-tumor-cells-in-breast-cancer-patients-treated-by-neoadjuvant-chemotherapy-a-meta-analysis
#8
François-Clément Bidard, Stefan Michiels, Sabine Riethdorf, Volkmar Mueller, Laura J Esserman, Anthony Lucci, Bjørn Naume, Jun Horiguchi, Rafael Gisbert-Criado, Stefan Sleijfer, Masakazu Toi, Jose A Garcia-Saenz, Andreas Hartkopf, Daniele Generali, Françoise Rothé, Jeffrey Smerage, Laura Muinelo-Romay, Justin Stebbing, Patrice Viens, Mark Jesus M Magbanua, Carolyn S Hall, Olav Engebraaten, Daisuke Takata, José Vidal-Martínez, Wendy Onstenk, Noriyoshi Fujisawa, Eduardo Diaz-Rubio, Florin-Andrei Taran, Maria Rosa Cappelletti, Michail Ignatiadis, Charlotte Proudhon, Denise M Wolf, Jessica B Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Yvonne Brucker, Karsten Weber, Fabien Reyal, Dominic Amara, Mandar G Karhade, Randi R Mathiesen, Hideaki Tokiniwa, Antonio Llombart-Cussac, Alessandra Meddis, Paul Blanche, Koenraad d'Hollander, Klaus Pantel
Background: We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker. Methods: We collected individual patient data from 21 studies in which CTC detection by CellSearch was performed in early breast cancer patients treated with NCT. The primary end point was overall survival, analyzed according to CTC detection, using Cox regression models stratified by study...
April 12, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29659611/preoperative-evaluation-of-the-efficacy-of-radio-hyperthermo-chemotherapy-for-soft-tissue-sarcoma-in-a-case-series
#9
Hisaki Aiba, Satoshi Yamada, Jun Mizutani, Norio Yamamoto, Hideki Okamoto, Katsuhiro Hayashi, Hiroaki Kimura, Akihiko Takeuchi, Shinji Miwa, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Yoshihiro Araki, Hiroyuki Tsuchiya, Takanobu Otsuka
PURPOSE: Radio-hyperthermo-chemo (RHC) therapy, which combines radiotherapy, hyperthermia, and chemotherapy, for malignant soft tissue tumors has been introduced with the aim of decreasing the possibility of local recurrence after surgery. To avoid unnecessary neoadjuvant therapy and to plan the appropriate surgical treatment, surveillance of RHC therapeutic efficacy during treatment is necessary. In this study, we determined the optimal response criteria to evaluate the efficacy of RHC by comparing preoperative images before and after RHC with pathological evaluation of necrosis in the resected tumor...
2018: PloS One
https://www.readbyqxmd.com/read/29658612/let-7d-3p-is-associated-with-apoptosis-and-response-to-neoadjuvant-chemotherapy-in-ovarian-cancer
#10
Raúl García-Vázquez, Dolores Gallardo Rincón, Erika Ruiz-García, Abelardo Meneses García, Olga N Hernández De La Cruz, Horacio Astudillo-De La Vega, David Isla-Ortiz, Laurence A Marchat, Yarely M Salinas-Vera, Ángeles Carlos-Reyes, Sullivan López-González, Rosalio Ramos-Payan, César López-Camarillo
Altered expression of microRNAs contributes to the heterogeneous biological behavior of human malignancies and it may correlate with the clinical pathological features of patients. The let-7 microRNA family is frequently downregulated in human cancers and its aberrant expression may be a useful marker for prediction of the clinical response to therapy in patients. In the present study, we analyzed the expression of three members of the let-7 family (let-7a-3p, let-7d-3p and let-7f), which remains largely uncharacterized in ovarian cancer tissues...
April 12, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29651946/neoadjuvant-therapy-is-essential-for-resectable-pancreatic-cancer
#11
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Shuo Li, Quan-Xing Ni, Xian-Jun Yu, Liang Liu
BACKGROUND: Awareness of the benefits of neoadjuvant therapy is increasing, but its use as an initial therapeutic option for patients with resectable pancreatic cancer remains controversial, especially for those patients without high-risk prognostic features. Even for patients with high-risk features who are candidates to receive neoadjuvant therapy, no standard regimen exists. METHODS: In this review, we examined available data on neoadjuvant therapy in patients with resectable pancreatic cancer, including prospective studies, retrospective studies, and ongoing clinical trials, by searching PubMed/MEDLINE, ClinicalTrials...
April 12, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29651796/oncological-impact-of-neoadjuvant-hormonal-therapy-on-permanent-iodine-125-seed-brachytherapy-in-patients-with-low-and-intermediate-risk-prostate-cancer
#12
Atsushi Takamoto, Ryuta Tanimoto, Kensuke Bekku, Motoo Araki, Takuya Sadahira, Koichiro Wada, Shin Ebara, Norihisa Katayama, Hiroyuki Yanai, Yasutomo Nasu
OBJECTIVES: To determine whether neoadjuvant hormonal therapy improves oncological outcomes of patients with localized prostate cancer treated with permanent brachytherapy. METHODS: Between January 2004 and November 2014, 564 patients underwent transperineal ultrasonography-guided permanent iodine-125 seed brachytherapy. We retrospectively analyzed low- or intermediate-risk prostate cancer based on the National Comprehensive Cancer Network guidelines. The clinical variables were evaluated for influence on biochemical recurrence-free survival, progression-free survival, cancer-specific survival and overall survival...
April 12, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29650420/denosumab-treatment-of-inoperable-or-locally-advanced-giant-cell-tumor-of-bone-multicenter-analysis-outside-clinical-trial
#13
Piotr Rutkowski, Louie Gaston, Aneta Borkowska, Silvia Stacchiotti, Hans Gelderblom, Giacomo Giulio Baldi, Emanuela Palmerini, Paolo Casali, Alessandro Gronchi, Michael Parry, Domenico Andrea Campanacci, Guido Scoccianti, Michal Wagrodzki, Stefano Ferrari, Sander Dijkstra, Andrzej Pieńkowski, Robert Grimer
BACKGROUND: Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB patients treated with denosumab in routine practice in 6 European reference centers. METHODS: Patients with locally advanced, unresectable or metastatic GCTB, treated with denosumab outside clinical trials were eligible. Primary end-point was progression-free survival (PFS) for all patients; secondary end-points were: type of surgery, relapse rate and event-free survival for patients after preoperative denosumab + surgery...
March 31, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29650132/optimal-timing-of-chemotherapy-and-surgery-in-patients-with-muscle-invasive-bladder-cancer-and-upper-urinary-tract-urothelial-carcinoma
#14
REVIEW
William Tabayoyong, Roger Li, Jianjun Gao, Ashish Kamat
Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for patients with clinically localized muscle-invasive bladder cancer. Survival after radical cystectomy is associated with final pathologic staging. Survival decreases with increasing pT stage because of the presence of occult micrometastases, indicating the need for systemic chemotherapy. Systemic chemotherapy is delivered as either neoadjuvant therapy preoperatively, or as adjuvant therapy postoperatively. This article reviews the evidence for neoadjuvant and adjuvant chemotherapy for the treatment of muscle-invasive bladder and upper tract urothelial cancer and offers recommendations based on these data and recently updated clinical guidelines...
May 2018: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29644477/the-selective-use-of-radiation-therapy-in-rectal-cancer-patients
#15
REVIEW
Andrew Martella, Christopher Willett, Manisha Palta, Brian Czito
PURPOSE OF REVIEW: Colorectal cancer has a high global incidence, and standard treatment employs a multimodality approach. In addition to cure, minimizing treatment-related toxicity and improving the therapeutic ratio is a common goal. The following article addresses the potential of omitting radiotherapy in select rectal cancer patients. RECENT FINDINGS: Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II-III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29644426/-ca19-9-in-intrahepatic-cholangiocarcinoma-a-diagnostic-and-prognostic-armamentarium
#16
B Juntermanns, G M Kaiser, S Itani Gutierrez, M Heuer, M Buechter, A Kahraman, H Reis, S Kasper, A Paul, C D Fingas
BACKGROUND: Intrahepatic cholangiocarcinomas are the second most common malignant tumors of the liver with an unfavorable prognosis. The role of CA19-9 in terms of patient prognosis is still under debate in the literature. OBJECTIVE: The aim of the present study was to investigate the prognostic value of preoperatively assessed CA19-9 levels in patients with intrahepatic cholangiocarcinoma after surgery. MATERIAL AND METHODS: A total of 63 patients suffering from intrahepatic cholangiocarcinoma underwent surgery between March 2001 and February 2013 at the West German Cancer Center in Essen, Germany...
April 11, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29644039/giant-anorectal-condyloma-acuminatum-of-buschke-l%C3%A3-wenstein-presents-difficult-management-decisions
#17
Hyunyoung G Kim, Jennifer E Kesey, John A Griswold
Condyloma acuminata, or anogenital warts, caused by human papillomavirus are the most common sexually transmitted disease. In rare cases, the disease could progress to an extensive neoplasm called Buschke-Löwenstein tumor (BLT), also known as giant condyloma acuminatum. BLT differs from normal condyloma acuminata by presenting with locally invasive growth, lack of spontaneous resolution, tendency for recurrence after treatment and potential for malignant transformation. We examine a BLT case reaching large dimensions in the anorectal region treated with neoadjuvant chemoradiation therapy and surgical excision of residual lesions...
April 2018: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29629335/intraoperative-radiation-boost-to-the-surgical-resection-bed-following-pancreaticoduodenectomy-for-a-borderline-resectable-pancreatic-carcinoma-a-case-report
#18
Tarita O Thomas, William Small, Mark Fleming, Song Kang, Richard A Hoefer
Neoadjuvant therapy including chemotherapy alone or concurrent chemotherapy with external bream radiation is a standard treatment strategy for borderline resectable pancreatic adenocarcinoma and is also used routinely for primary operable cancers at some institutions (1). The use of intraoperative radiation therapy (IORT) has been limited largely because of the logistical issues in delivery of radiation during surgery (2). This is the first reported case of a borderline resectable pancreas cancer patient who underwent neoadjuvant chemo-radiation therapy followed by resection with the use of IORT using the mobile IntraBeam device to boost the resection bed and improve local control by dose escalation...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29629317/surgical-management-of-neuroendocrine-tumor-associated-liver-metastases-a-review
#19
REVIEW
Miu Yee Chan, Ka Wing Ma, Albert Chan
Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies. This article aims to review the current evidence available, together with some latest updates, focusing on the surgical management.
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29625841/safety-and-efficacy-of-preoperative-or-postoperative-chemotherapy-for-resectable-pancreatic-adenocarcinoma-pact-15-a-randomised-open-label-phase-2-3-trial
#20
Michele Reni, Gianpaolo Balzano, Silvia Zanon, Alessandro Zerbi, Lorenza Rimassa, Renato Castoldi, Domenico Pinelli, Stefania Mosconi, Claudio Doglioni, Marta Chiaravalli, Chiara Pircher, Paolo Giorgio Arcidiacono, Valter Torri, Paola Maggiora, Domenica Ceraulo, Massimo Falconi, Luca Gianni
BACKGROUND: Pancreatic ductal adenocarcinoma are known to metastasise early and a rationale exists for the investigation of preoperative chemotherapy in patients with resectable disease. We aimed to assess the role of combination chemotherapy in this setting in the PACT-15 trial. METHODS: We did this randomised, open-label, phase 2-3 trial in ten hospitals in Italy. We report the phase 2 part here. Patients aged 18-75 years who were previously untreated for pancreatic ductal adenocarcinoma, with Karnofsky performance status of more than 60, and pathologically confirmed stage I-II resectable disease were enrolled...
April 3, 2018: Lancet. Gastroenterology & Hepatology
keyword
keyword
97139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"